# The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)

> **NCT01449019** · PHASE1 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** exendin(9-39)amide
- **DRUG:** saline
- **OTHER:** duodenal meal
- **OTHER:** duodenal saline

## Key facts

- **NCT ID:** NCT01449019
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-08
- **Final completion:** 2010-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449019, "The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01449019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*